Cancer-associated extramedullary hematopoiesis is increasingly recognized as a systemic mechanism of immune evasion. Although the spleen is an important site of tumor-induced myelopoiesis, how this process is locally maintained remains incompletely understood. In this issue of the JCI, Zhu and colleagues identify a self-reinforcing circuit between tumor-associated neutrophils and splenic hematopoietic stem and progenitor cells (HSPCs). They show that neutrophil-derived, NOX2-dependent ROS activated forkhead box O1 (FOXO1) in neighboring HSPCs, inducing dynamin-related protein 1 dependent (DRP1-dependent) mitochondrial fission and a myeloid-biased, granulocyte-macrophage CSF–producing (GM-CSF–producing) progenitor state. The resulting neutrophil progeny further reinforced oxidative stress, thereby sustaining immunosuppressive myelopoiesis in the spleen. Disruption of this circuit through genetic, pharmacologic, or spleen-directed interventions reduced suppressive myeloid cell production, enhanced cytotoxic T cell activity, and restrained tumor growth. These findings establish mature neutrophils as active regulators of pathological splenic hematopoiesis and identify the neutrophil/ROS/FOXO1/DRP1 axis as a potential therapeutic target in cancer.
Hongpeng Jia
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.